IMMY - Imprimis Pharmaceuticals, Inc.

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
1.68
-0.06 (-3.17%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close1.74
Open1.73
Bid1.63 x 27300
Ask1.75 x 4200
Day's Range1.62 - 1.75
52 Week Range1.35 - 4.69
Volume67,810
Avg. Volume505,208
Market Cap34.5M
Beta1.49
PE Ratio (TTM)N/A
EPS (TTM)-0.84
Earnings DateMar 8, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.00
Trade prices are not sourced from all markets
  • Imprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. EST
    PR Newswire6 days ago

    Imprimis Pharmaceuticals to Host its Fourth Quarter 2017 Financial Report Conference Call and Webcast on March 8, 2018 at 4:30 p.m. EST

    SAN DIEGO, Feb. 15, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release fourth quarter 2017 financial results after the close of trading on Thursday, March 8, 2018.  The company will host a conference call at 4:30 p.m. EST/1:30 p.m. PST on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (877) 407-8035 for domestic callers or (201) 689-8035 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Imprimis website at www.ImprimisRx.com.  A dial in replay of the call will be available until April 8, 2018.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 25720.  The webcast replay will be available until June 8, 2018.

  • ACCESSWIRE21 days ago

    Today’s Research Reports on Trending Tickers: Corbus Pharmaceuticals and Imprimis Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / January 31, 2018 / U.S. markets fell sharply Tuesday for the second consecutive day. Both the Dow Jones and S&P 500 experienced their largest one day drop of 2018. The Dow Jones ...

  • Who Owns Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)?
    Simply Wall St.21 days ago

    Who Owns Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)?

    I am going to take a deep dive into Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) most recent ownership structure, not a frequent subject of discussion among individual investors. Ownership structure has beenRead More...

  • Imprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs on FDA's Drug Shortage List
    PR Newswire22 days ago

    Imprimis Pharmaceuticals Now Making Available Two Glaucoma Drugs on FDA's Drug Shortage List

    SAN DIEGO, Jan. 30, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced that it is now dispensing preservative-free dorzolamide and a preservative-free dorzolamide/timolol formulation after dorzolamide and the commercial products, Cosopt® and Cosopt® PF, were added to the FDA Drug Shortage List.

  • ACCESSWIRE26 days ago

    Blog Exposure - Imprimis Pharma Received DEA Manufacturer Certificate for 503B Outsourcing Facility

    LONDON, UK / ACCESSWIRE / January 26, 2018 / Active-Investors.com has just released a free research report on Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY ). If you want access to this report all you need ...

  • Imprimis Pharmaceuticals is Issued DEA Manufacturer Certificate for its 503B Outsourcing Facility
    PR Newswire28 days ago

    Imprimis Pharmaceuticals is Issued DEA Manufacturer Certificate for its 503B Outsourcing Facility

    SAN DIEGO, Jan. 24, 2018 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced that following inspection by the US Drug Enforcement Administration, its New Jersey FDA-registered outsourcing facility has been issued a DEA Manufacturer Controlled Substance Registration Certificate. This new registration will further allow Imprimis to leverage its national compounding platform and its relationships with nearly 2,000 ophthalmology and optometric customers, including many of the largest ambulatory surgery centers in the US and numerous hospital systems, in order to provide patients and their healthcare professionals with affordable compounded formulations when they are clinically appropriate. By partnering with physicians to meet their patients' unmet needs, Imprimis continues to make progress in meeting its mission of bringing high quality innovative ophthalmic formulations to physicians and their patients.

  • What You Must Know About Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Financial Strength
    Simply Wall St.29 days ago

    What You Must Know About Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) Financial Strength

    Investors are always looking for growth in small-cap stocks like Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), with a market cap of $33.27M. However, an important fact which most ignore is: how financiallyRead More...

  • GlobeNewswirelast month

    Report: Exploring Fundamental Drivers Behind Hibbett Sports, Fox Factory Holding, Triangle Capital, Silgan, Imprimis Pharmaceuticals, and On Deck Capital — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Jan. 17, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Hibbett ...

  • Reuterslast month

    Imprimis receives FDA warning over eye medication advertising

    The U.S. Food and Drug Administration has issued a warning letter to Imprimis Pharmaceuticals Inc accusing it of making false or misleading claims that its compounded eye medications had the agency's approval. The Dec. 21 letter to San Diego-based Imprimis was posted on the FDA's website on Tuesday. Imprimis is contesting a lawsuit by rival Allergan Plc over allegations it is illegally selling and advertising unapproved drugs.

  • NasdaqCM Healthcare Industry: A Deep Dive Into Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)
    Simply Wall St.last month

    NasdaqCM Healthcare Industry: A Deep Dive Into Imprimis Pharmaceuticals Inc (NASDAQ:IMMY)

    Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), a USD$37.99M small-cap, operates in the healthcare industry, which continues to be affected by the sustained economic uncertainty and structural trends, such as an aging population,Read More...

  • Is Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Pay Justified?
    Simply Wall St.2 months ago

    Is Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) CEO Pay Justified?

    Mark Baum is the CEO of Imprimis Pharmaceuticals Inc (NASDAQ:IMMY), which has recently grown to a market capitalization of $35.53M. Recognizing whether CEO incentives are aligned with shareholders is aRead More...

  • Capital Cube2 months ago

    ETFs with exposure to Imprimis Pharmaceuticals, Inc. : December 26, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Imprimis Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IMMY-US. Comparing the performance and risk of Imprimis Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Imprimis Pharmaceuticals Inc (IMMY): Has Recent Earnings Growth Beaten Long-Term Trend?
    Simply Wall St.3 months ago

    Imprimis Pharmaceuticals Inc (IMMY): Has Recent Earnings Growth Beaten Long-Term Trend?

    For investors, increase in profitability and industry-beating performance can be essential considerations in an investment. Below, I will examine Imprimis Pharmaceuticals Inc’s (NASDAQ:IMMY) track record on a high level, toRead More...

  • Associated Press3 months ago

    Imprimis reports 3Q loss

    The San Diego-based company said it had a loss of 28 cents per share. The pharmaceutical and drug compounding company posted revenue of $6.5 million in the period. The company's shares closed at $1.66. ...

  • Imprimis Pharmaceuticals Announces Third Quarter 2017 Results
    PR Newswire3 months ago

    Imprimis Pharmaceuticals Announces Third Quarter 2017 Results

    SAN DIEGO , Nov. 14, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY), an ophthalmology-focused pharmaceutical company, today reported financial results for the third quarter 2017.  Third ...

  • ACCESSWIRE3 months ago

    Investor Network Invites You to the Imprimis Pharmaceuticals Third Quarter 2017 Earnings Conference Call and Webcast Live on Tuesday, November 14, 2017

    SAN DIEGO, CA / ACCESSWIRE / November 13, 2017 / Imprimis Pharmaceuticals, Inc. (NASDAQ: IMMY) will host a conference call and live webcast to discuss the results of the third quarter 2017, to be held ...

  • Capital Cube3 months ago

    ETFs with exposure to Imprimis Pharmaceuticals, Inc. : November 10, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Imprimis Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IMMY-US. Comparing the performance and risk of Imprimis Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)

  • Imprimis Pharmaceuticals to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. EST
    PR Newswire4 months ago

    Imprimis Pharmaceuticals to Host its Third Quarter 2017 Financial Report Conference Call and Webcast on November 14, 2017 at 4:15 p.m. EST

    SAN DIEGO, Oct. 31, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it will release third quarter 2017 financial results after the close of trading on Tuesday, November 14, 2017.  The company will host a conference call at 4:15 p.m. EST/1:15 p.m. PST on the same day to discuss the financial results and recent business developments. To participate in the call, please dial (877) 407-8035 for domestic callers or (201) 689-8035 for international callers.  To listen to the webcast, please click here or visit the investor relations section of the Imprimis website at www.ImprimisRx.com.  A dial in replay of the call will be available until December 14, 2017.  To access the replay, dial (877) 481-4010 domestically or (919) 882-2331 internationally and reference Replay ID: 22220.  The webcast replay will be available until February 14, 2018.

  • Imprimis Launches Surface Pharmaceuticals Subsidiary
    PR Newswire4 months ago

    Imprimis Launches Surface Pharmaceuticals Subsidiary

    SAN DIEGO, Oct. 24, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it has filed a Form 8-K with the SEC which contains a corporate presentation for its subsidiary, Surface Pharmaceuticals, Inc.  The Surface presentation is also available at www.SurfacePharma.com. Surface Pharmaceuticals intends to advance state of the art treatments for ocular surface diseases by seeking FDA approval for three drug candidates for up to five indications.  Surface's drug candidates were formulated using technology covered by two issued patents and three pending patent applications.  Certain Surface drug formulations have been prescribed as compounded drugs and have demonstrated considerable anecdotal human clinical success.  The markets for Surface's drug candidates include dry eye disease and blepharitis, both of which exceed 1 billion dollars in annual U.S. pharmaceutical sales.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Stocks to Watch: Alcobra and Imprimis Pharmaceuticals

    NEW YORK, NY / ACCESSWIRE / October 20, 2017 / Alcobra headed higher on Thursday after the company's wholly-owned subsidiary Arcturus entered into a research collaboration and worldwide license agreement ...

  • Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis®
    PR Newswire4 months ago

    Imprimis Pharmaceuticals to Offer Compounded Cyclosporine Alternative to Restasis®

    Dry Eye Disease is estimated to affect up to 30 million Americans and is commonly characterized by irritated, gritty, scratchy or burning eyes, blurred vision, and feeling particles in the eye when there are none. Advanced Dry Eye Disease may damage the front surface of the eye and ultimately impair vision.

  • What’s The Outlook For Loss-Making Imprimis Pharmaceuticals Inc (IMMY)?
    Simply Wall St.5 months ago

    What’s The Outlook For Loss-Making Imprimis Pharmaceuticals Inc (IMMY)?

    Imprimis Pharmaceuticals Inc (NASDAQ:IMMY) continues its loss-making streak, announcing a -$13.47M earnings for its latest financial year ending. Since IMMY is currently burning more cash than it is making, it’sRead More...

  • Imprimis Pharmaceuticals Secures First Key Composition Patent for Dropless Therapy® Formulations
    PR Newswire5 months ago

    Imprimis Pharmaceuticals Secures First Key Composition Patent for Dropless Therapy® Formulations

    SAN DIEGO, Oct. 2, 2017 /PRNewswire/ -- Imprimis Pharmaceuticals, Inc. (IMMY), an ophthalmology-focused pharmaceutical company, today announced it has secured its first patent covering the company's innovative Dropless Therapy® formulations from the Australian Patent office, a division of IP Australia.  Patent 2014293665, "Pharmaceutical compositions for intraocular administration comprising an antibacterial agent and an anti-inflammatory agent" will expire March 27, 2034, not including any potential extensions.

  • Capital Cube5 months ago

    ETFs with exposure to Imprimis Pharmaceuticals, Inc. : September 22, 2017

    Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Imprimis Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IMMY-US. Comparing the performance and risk of Imprimis Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)